General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Revenue of ₹162.35 crore, operating profit of ₹41.02 crore, PAT of ₹25.62 crore. Against the year-ago June quarter — ₹111.48 crore, ₹24.17 crore and ₹11.93 crore — that is revenue up 45.6%, operating profit up 69.7% and profit after tax up 114.8%. Sequentially, against the March 2026 quarter, revenue rose 3.3% and PAT 1.3%, which after the YoY column feels like the quarter took a short nap.
The rest of the quarter was less restful. Thirteen bioequivalence studies were completed — seven from the General unit, two from Beta Lactam, four from Oncology — inside a programme covering 40 molecules. Fifteen-plus new product registrations landed across Malaysia, Algeria, Peru and Mexico. Pembrolizumab received approval to begin pre-clinical batches. Erythropoietin moved to clinical trial stage. And in May 2026, ICRA upgraded the company’s long-term rating from [ICRA]B+ (Stable) to [ICRA]BBB+ (Stable), removing it from the Issuer Not Cooperating category — a five-notch move that also involved the company agreeing to answer the phone.
Management has raised FY27 guidance to revenue of ₹700+ crore, EBITDA of ₹189–196+ crore and PAT of ₹109+ crore. The FY26 base for those: ₹503.08 crore of revenue and ₹67.35 crore of net profit.
2. Introduction
Kwality Pharmaceuticals was incorporated in 1983 in Amritsar, which means the company has now been making medicine for longer than most of its 1,750-odd employees have been alive. Per ICRA, it began as a private limited company promoted by Mr. Ramesh Arora, was reconstituted as a closely held public limited company in 1993, listed on the BSE SME platform in July 2016, and migrated to the BSE main board in June 2022. Four decades of pharmaceutical manufacturing preceded the ticker by thirty-three years.
The last several years read as a steady accumulation of certificates. Per the company’s presentation, the journey markers run: beta lactam and biological units established around 2020–2022, EU GMP for injectables, PIC/S GMP approvals, SFDA approval for the General and Beta Lactam units, and in the most recent year EU-GMP approval for the general and beta lactam plants. Four of five manufacturing plants are EU-GMP approved. Cumulative regulatory filings have gone from 75 in FY23 to 700+, with 200 filed in FY26 alone.
Revenue over the same window: ₹251 crore in FY23, ₹307 crore in FY24, ₹370 crore in FY25, ₹503 crore in FY26. Net profit across those years: ₹19.37 crore, ₹23.80 crore, ₹39.85 crore, ₹67.35 crore.
The record also holds a harder entry. In October 2023 the company disclosed a fire accident at its Amritsar plant involving employee fatalities, and filed an update on resumption of operations that same month.
More recently: an investor knowledge session held on 10 August 2026, an earnings call transcript filed 12 August, the notice of the 43rd Annual General Meeting published the same day, and the newspaper publication of Q1 FY27 results on 13 August. A company that files its own newspaper advertisements is a company that has been doing this a while.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
They make medicines, in almost every physical shape a medicine can take. The company states a portfolio of 1,000+ formulations across 25+ therapeutic areas — the older Screener commentary says 3,000+, and both numbers appear in the record. Dosage forms, per the FY26 mix: injectables 48% of revenue, tablets 38%, capsules 5%, liquid externals and oral liquids 3%, creams and ointments 2%, and then dry syrups, ophthalmics, sachets and suppositories at 1% each. Someone in Amritsar is running a suppository line that generates one percent of a ₹503 crore business, and that line has to hit EU GMP standards anyway.
Five units across two campuses. Campus 1 in Amritsar holds Unit 1 (General Formulations), Unit 2 (Beta Lactam) and Unit 5 (Biologics); Campus 2 in Himachal Pradesh holds Unit 3 (Oncology) and Unit 4 (Cephalosporins). The stated annual capacities are the kind of numbers that stop meaning anything: 3,000 million tablets and 1,500 million capsules from the beta lactam unit alone, 200 million ampoules and 200 million vials from Unit 1, plus 40 million dental cartridges, because apparently dentists needed their own line.
Manufacturing revenue for FY26 splits: Unit 1 (General) 60%, Unit 3 (Oncology) 26%, Unit 2 (Beta Lactam) 10%, Unit 4 (Cephalosporins) 4%.
The commercial model is 90% out-licensing and supply, 10% CDMO. Rather than build front-end sales teams in seventy countries, the company registers products and sells to 100+ clients who own the shelf space. Per ICRA, exports generate around 50% of annual revenues, across semi-regulated markets in Asia, Africa and Latin America with an evolving presence in Europe — and many domestic customers re-export, so the export figure understates itself.
Management’s stated logic is dossier arithmetic: get a registration in a highly regulated country, then reuse the same dossier across 60 or 70 filings. Each registration is framed as contributing roughly USD 1.5–2 million of annual sales. They said they received almost 60–70 registrations over the last three quarters. The accreditation list — ANVISA, INVIMA, COFEPRIS, SFDA, DIGEMID, plus regulators in Zimbabwe, Malawi, Yemen, Ivory Coast and Kurdistan — reads less like a
